Manejo del paciente en prevención secundaria con factores de riesgo cardiovascular e insuficiencia cardíaca

1. Adheridos al control y la vida. Disponible en: Adheridos al control y la vida – Plataforma Adheridos Servier (último acceso junio 2024)
2. Bansilal S, Castellano JM, Garrido E, et al. Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes. J Am Coll Cardiol. 2016 Aug 23;68(8):789-801.
3. Barrios V, Castellanos M, Campuzano Ruiz R, et al. Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study. Front Cardiovasc Med. 2022 Aug 4;9:966049.
4. Böhm M, Abdin A, Slawik J, et al. Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2023 Aug;25(8):1429-1435.
5. Campuzano R, Barrios V, Mostaza JM, et al. Preliminary results from REALITY: a nation-wide study of a database with 1.8 million real-life patients to study atherosclerotic cardiovascular disease and familial hypercholesterolemia in Spain. European Heart Journal. 2022 Oct 3;43(Supplement_2)
6. Campuzano R. Reality Study. Análisis nacional en vida real de 1.8 millones personas para el estudio de la enfermedad cardiovascular aterosclerótica y la hipercolesterolemia familiar en España. Disponible en: https://areacapacita.com/materiales/cursomevcap1ed/03-apuntes-2.pdf (último acceso junio 2024)
7. Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014 Nov 18- 25;64(20):2071-82.
8. Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022 Sep 15;387(11):967-977.
9. Cordero A, Fernández Olmo R, Badimon L, et al. The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events. J Clin Lipidol. 2023 Sep-Oct;17(5):602-611.
10. Cosín-Sales J, Campuzano Ruiz R, Díaz Díaz JL, et al. Impact of physician’s perception about LDL cholesterol control in clinical practice when treating patients in Spain. Atherosclerosis. 2023 Jun;375:38-44.
11. De Luca L, Riccio C, Navazio A, et al. ANMCO position paper on the management of hypercholesterolaemia in patients with acute coronary syndrome. Eur Heart J Suppl. 2023 May 18;25(Suppl D):D312-D322.
12. Docherty KF, Shen L, Castagno D, et al. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. Eur J Heart Fail. 2020 Mar;22(3):528-538.
13. Domanski MJ, Tian X, Wu CO, et al. Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk. J Am Coll Cardiol. 2020 Sep 29;76(13):1507-1516.
14. ElSayed NA, Aleppo G, Aroda VR, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S158-S190.
15. Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011 Oct;32(19):2395-404.
16. Escobar C, Anguita M, Arrarte V, et al. Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology. Rev Esp Cardiol (Engl Ed). 2020 Feb;73(2):161-167.
17. Facila Rubio L, Bonanad Lozano C, Arrarte Esteban V, et al. Protocolo al alta en pacientes con diabetes mellitus tipo 2 y enfermedad cardiovascular. Disponible en:
https://static1.squarespace.com/static/56895ce240667a38691c2539/t/62156a624e315f603fd85d44/1645570702224/Protocolo+al+alta+DM2+y+SCA.pdf (último acceso junio 2024)
18. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459-2472.
19. Ficha técnica Ivabradina. Disponible en: https://www.ema.europa.eu/es/documents/product-information/procoralan-epar-product-information_es.pdf (último acceso junio 2024)
20. Gencer B, Mach F. So low… so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors. Eur Heart J. 2018 Feb 1;39(5):382-384.
21. Gencer B, Mach F, Guo J, et al. Cognition After Lowering LDL-Cholesterol With Evolocumab. J Am Coll Cardiol. 2020 May 12;75(18):2283-2293.
22. Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved
Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018 Apr 10;137(15):1571-1582.
23. Giugliano RP, Wiviott SD, Blazing MA, et al. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. JAMA Cardiol. 2017 May
1;2(5):547-555.
24. Guía ESC/EAS 2019 sobre el tratamiento de las dislipemias: modificación de los lípidos para reducir el riesgo cardiovascular. Rev Esp Cardiol. 2020;73(5):403.e1-403.e70.
25. Hansson GK. Inflammation and Atherosclerosis: The End of a Controversy. Circulation. 2017 Nov 14;136(20):1875-1877.
26. Herrett E, Williamson E, Brack K, et al. The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs. Health Technol Assess. 2021 Mar;25(16):1-62.
27. Herrett E, Williamson E, Brack K, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021 Feb 24;372:n135.
28. Hidalgo FJ, Anguita M, Castillo JC, et al. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study. Int J Cardiol. 2016 Aug 15;217:7-11.
29. Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease
(RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022 Jul 30;400(10349):380-390.
30. Kondo T, Butt JH, Curtain JP, et al. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circ Heart Fail. 2023 Dec;16(12):e010898.
31. Lawler PR, Bhatt DL, Godoy LC, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021 Jan 1;42(1):113-131.
32. Lee YJ, Cho JY, You SC, et al. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. Eur Heart J. 2023 Ma 14;44(11):972-983.
33. Lee SH, Lee YJ, Heo JH, et al. Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis. J Am Coll Cardiol. 2023 Apr 11;81(14):1339-1349.
34. Leiter LA, Bays H, Conard S, et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol. 2008 Dec 1;102(11):1495-501.
35. Lopatin YM, Cowie MR, Grebennikova AA, et al. Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program. Int J Cardiol. 2018 Jun 1;260:113-117.
36. Masana L, Ibarretxe D, Plana N. Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets: Lipid-lowering combination therapy. Curr Cardiol Rep. 2020 Jun 19;22(8):66.
37. Masana L, Plana N, Andreychuk N, Ibarretxe D. Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment. Pharmacol Res. 2023 Apr;190:106738.
38. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726.
39. Mostaza JM, Pintó X, Armario P, et al. Standards for global cardiovascular risk management arteriosclerosis. Clin Investig Arterioscler. 2019 Jul;31 Suppl 1:1-43.
40. Müller-Werdan U, Stöckl G, Werdan K. Advances in the management of heart failure: the role of ivabradine. Vasc Health Risk Manag. 2016 Nov17;12:453-470.
41. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023 Nov 14;148(20):1606-1635.
42. Pedro-Botet J, Pintó X. LDL-cholesterol: The lower the better. Clin Investig Arterioscler. 2019 Dec;31 Suppl 2:16-27.
43. Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019 Mar 14;380(11):1022-1032.
44. Ray KK, Molemans B, Schoonen WM, et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021 Sep 20;28(11):1279-1289.
45. Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022 Feb 22;43(8):830-833.
46. Sanfélix-Gimeno G, Peiró S, Ferreros I, et al. Adherence to evidence-based therapies after acute coronary syndrome: a retrospective population-based cohort study linking hospital, outpatient, and pharmacy health information systems in Valencia, Spain. J Manag Care Pharm. 2013 Apr;19(3):247-57.
47. SEC. CardioTV. Insights del estudio REALITY. Disponible en: https://secardiologia.es/multimedia/directos-online/ciclos/reaprendiendo-de-lipidos/13574-estudio-reality (último acceso junio 2024)
48. Schubert J, Lindahl B, Melhus H, et al. Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J. 2021 Jan 20;42(3):243-252.
49. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010 Sep 11;376(9744):875-85.
50. Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013 Sep 4;310(9):918-29.
51. Tsujita K, Sugiyama S, Sumida H, et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol. 2015 Aug 4;66(5):495-507.
52. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337.
53. Wilkinson MJ, Lepor NE, Michos ED. Evolving Management of Low-Density Lipoprotein Cholesterol: A Personalized Approach to Preventing
Atherosclerotic Cardiovascular Disease Across the Risk Continuum. J Am Heart Assoc. 2023 Jun 6;12(11):e028892.
Basado en la experiencia clínica del Dr. Ángel Iniesta y el Dr. Lorenzo Fácila.